Natco Pharma declares interim dividend of ₹1.50/share; sets Feb 18 as record date
Natco Pharma declared a third interim dividend of ₹1.50 per equity share for FY2025-26. The record date for determining eligible shareholders is set as February 18, 2026. Dividend payments will commence from February 26, 2026.
Dividend announcements can positively influence investor sentiment and stock price, but the impact is medium as it is an interim dividend and the amount is relatively small per share.
The declaration of an interim dividend is generally viewed positively by investors as it indicates the company's profitability and willingness to return value to shareholders.
Natco Pharma Limited announced that its Board of Directors, in a meeting held on February 12, 2026, declared a third interim dividend of ₹1.50 per equity share. This dividend amounts to 75% of the face value of ₹2 per share for the financial year 2025-26.
The company has fixed Wednesday, February 18, 2026, as the record date to determine the eligibility of shareholders for this interim dividend payment. The disbursement of the declared interim dividend is scheduled to commence on February 26, 2026.
This announcement was made by Ch. Venkat Ramesh, Company Secretary & Compliance Officer of Natco Pharma Limited.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.